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Objective Presence of lung metastases in low-risk gestational
trophoblastic neoplasia (GTN) is generally considered not to
influence prognosis. However, in a recent study in the
Netherlands, GTN patients with lung metastases had a higher
recurrence rate and more disease-specific deaths compared with
patients without metastases. The aim of the present study was to
validate these findings in a different country.
Design Historical cohort study.
Setting Charing Cross Hospital, United Kingdom.
Population A total of 1040 low-risk GTN patients treated with
methotrexate (MTX) between 2002 and 2016 were identified: 65
with lung metastases (group 1) and 975 without metastases
(group 2).
Methods Baseline characteristics, MTX resistance, survival and
recurrence rates were recorded and compared between both
groups.
Main outcome measures MTX resistance, recurrence rate and
survival.
Results The occurrence of MTX resistance and median number of
MTX courses to achieve remission was significantly higher in
patients with lung metastases than patients without metastases
(60% versus 38.9%, P = 0.001; and nine versus six courses,
P < 0.001). All choriocarcinoma patients (n = 4) with lung
metastases developed MTX resistance. The recurrence rate was
also higher in group I (9.2% versus 2.7%; P = 0.012). Disease-
specific survival was 100% in both groups.
Conclusions The presence of lung metastases at the start of MTX
therapy is associated with increased incidence of MTX resistance
and recurrence in low-risk GTN without affecting overall survival,
which remains 100%. However, individuals with low-risk
choriocarcinoma with lung metastases are likely to become
resistant to MTX and primary multi-agent chemotherapy should
be considered.
Keywords Gestational trophoblastic neoplasia, lung metastases,
methotrexate, recurrence.
Tweetable abstract The presence of lung metastases appears to
increase the risk of recurrence in low-risk GTN, but does not
affect overall cure rates and survival.
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Introduction
Gestational trophoblastic neoplasia (GTN) is a relatively
rare malignant condition that comprises entities such as:
persistently increased human chorionic gonadotrophin
(hCG) after molar pregnancy, non-molar choriocarcinoma,
placental site trophoblastic and epithelioid trophoblastic
tumours (PSTT/ETT).1 Treatments have evolved so that
GTN is now a disease with high cure rates even in the
presence of metastatic disease.2–5 According to the criteria
of the International Federation of Gynecology and Obstet-
rics (FIGO), post-molar GTN is diagnosed when one of the




following is present: (1) a plateau of at least four persis-
tently elevated hCG values during 3 weeks, (2) a sequential
rise of three hCG values for 2 weeks or longer, (3) histo-
logical diagnosis of choriocarcinoma.2,6 GTN is treated
with either single-agent or multi-agent chemotherapy,
which in nearly all parts of the world is selected using the
FIGO 2000 scoring system. This enables the stratification of
individuals based on whether they have a low or high risk
of developing resistance to single-agent chemotherapy.6,7 In
the Netherlands, a clinical scoring system was used until
recently.8,9 In both the FIGO and Dutch clinical scoring
systems, the lung as a site of metastases is not considered
to be an adverse prognostic factor. However, the total
number of metastases and the maximum tumour size,
which includes metastases in the lungs, can influence the
FIGO score and thereby impact on the selection of single-
agent versus multi-agent chemotherapy. A chest X-ray
(CXR) is recommended to assess lung metastases to evalu-
ate the risk score, and not chest computed tomography
(CT).2 In the recent study by Vree et al., patients with lung
metastases had a higher pre-evacuation level of hCG, more
recurrences and a higher chance of dying from their dis-
ease.9 As this study was performed using the Dutch scoring
system in a setting where the care of trophoblast patients is
not centralised in expert centres, this could have resulted
in a worse outcome with disease-specific deaths. Therefore,
we investigated the influence of lung metastases on the
course of disease in a centralised population treated in a
specialised trophoblastic disease centre that uses the FIGO
scoring system.
Patients and methods
In this retrospective cohort, all low-risk GTN patients trea-
ted initially with methotrexate (MTX) with either no
metastases or with lung metastases only, were selected from
the electronic database at the Charing Cross Hospital
between January 2002 and December 2016.
Figure 1 illustrates the patient selection process. No
patients with metastases elsewhere were included. All
patients had centralised pathological review by expert
pathologists. Patients with PSTT, ETT, mixed PSTT/ETT,
mixed PSTT/choriocarcinoma or mixed ETT/choriocarci-
noma were excluded from this study because these disease
entities behave and are treated differently.10,11 High-risk
patients (FIGO score ≥7) or relapsed low-risk patients fol-
lowing initial chemotherapy were excluded as they are also
treated differently.12 In addition, 35 low-risk patients trea-
ted with first-line therapy other than MTX were excluded to
keep the group as homogeneous as possible. All patients
were divided into two groups: those with only lung metas-
tases (group 1) and patients without any metastases (group
2). Those with lung metastases were included if their disease
was present on initial staging CXR and/or chest CT, without
other metastases at any time during the course of the dis-
ease. For the definition of GTN, the criteria of FIGO 2000
staging were used.13 After diagnosing post-molar GTN, a
Doppler ultrasound scan of the pelvis and CXR were per-
formed. If the CXR was abnormal, then a chest CT and an
MRI of the brain were undertaken. However, GTN follow-
ing any other type of pregnancy was investigated with CT of
chest/abdomen and MRI of head and pelvis, all with con-
trast, in addition to a Doppler ultrasound scan of the pelvis.
Women scoring ≤6 on the FIGO scoring system were trea-
ted with single-agent MTX and folinic acid (FA)
chemotherapy as previously described.14,15. Patient data
were collected on age, antecedent pregnancy, FIGO score,
pre-evacuation serum hCG concentrations, pre-chemother-
apy serum hCG concentrations, number of lung metastases,
the need for single- and multi-agent chemotherapy and the
number of courses necessary to achieve normalisation of
hCG concentrations. MTX resistance was defined as at least
three static or at least two rising serum hCG measure-
ments.15 Recurrence was defined as at least two serial rising
serum hCG measurements in the absence of a new preg-
nancy or other explanation after at least 6 weeks of normal
hCG values following completion of chemotherapy to
induce the first remission of disease. MTX resistance, recur-
rence and death from disease were recorded.
SPSS software (version 20) and R (version 3.5.0) were
used for statistical analysis. Antecedent pregnancies and
histopathological diagnosis were compared between
patients with and without lung metastases using Fisher
exact test. Differences in pre-treatment hCG concentra-
tions, days from evacuation to remission and number of
required chemotherapy regimens in patients cured with
MTX were calculated and compared between the patients
with and without lung metastases using Mann–Whitney U
test. Choice of first treatment and effectiveness of MTX
treatment, FIGO classification, recurrence of disease and
disease-specific survival were compared between both
Figure 1. Flow chart illustrating the patient selection process
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patient groups using Fisher exact test. Logistic regression
was used to assess the association between presence of lung
metastases and recurrence of disease (yes or no) and MTX
resistance (yes or no). Because the FIGO scoring system is
based on the values assigned to the different prognostic fac-
tors, FIGO score was used only in the univariate analysis.
Weighted logistic regression was used to estimate the causal
effect of the presence of lung metastases. This presence was
modelled with antecedent pregnancy, histopathological
diagnosis and interval from evacuation until treatment as
explanatory variables. Recurrence was analysed as a binary
(yes/no) outcome and crude percentages were reported.
The results from this method are valid under the assump-
tion that all patients have complete follow up.
No core outcome sets were relevant for this study. Fur-
thermore, there was no patient involvement in this retro-
spective study and no funding was received.
Results
A total of 65 low-risk GTN patients with lung metastases
(Group I) and 975 without metastases (Group II) were
included (Fig. 1). Patient characteristics are presented in
Table 1. A histological diagnosis of choriocarcinoma was
more often seen in the patients with lung metastases (6.2%
versus 1.7% P = 0.037). In contrast, complete molar preg-
nancies were more often associated with the absence of
lung metastasis (81% versus 67.7%, P = 0.015). Low-risk
patients with lung metastases had significantly higher pre-
evacuation serum hCG concentrations than patients with-
out metastases (median 85 701.50 IU/l versus median
9654 IU/l; P < 0.001), but the difference in pre-chemother-
apy serum hCG concentrations was not significant. Age,
antecedent pregnancy and the time interval from evacua-
tion to start of therapy did not differ between groups.
In patients with lung metastases, most had only one to
four lung lesions (n = 49), six had five to eight lesions and
only two had more than eight metastases. In eight patients,
the available reports simply stated the presence of ‘multiple
metastases’, but further validation was not possible because
these images were not accessible for review. The median
diameter of the largest lung tumour was 1.3 cm (range
0.6–4 cm). Eight patients had lung metastases only detected
by chest CT and not visible on CXR.
Treatment regimen and outcome are presented in
Table 2. Patients with lung metastases needed significantly
Table 1. Baseline characteristics of the participants







Age in years mean (SD) 31.5 (9.7) 32.4 (7.8) 0.366
Antecedent pregnancy
Mole* 58 (89.2%) 926 (95.0%) 0.106
Term 2 (3.1%) 15 (1.5%)
Miscarriage 5 (7.7%) 30 (3.1%)
Unknown 0 (0.0%) 4 (0.4%)
FIGO score
Median (IQR) 4 (3–5) 3 (1–4) <0.001
Interval from evacuation to start of treatment (months)
Median (IQR) 1 (1–2) 1 (1–2) 0.631
Histopathological diagnosis
Complete mole 44 (67.7%) 790 (81.0%) 0.003
Partial mole 6 (9.2%) 109 (11.2%)
Mole* 7 (10.8%) 37 (3.8%)
Choriocarcinoma 4 (6.2%) 17 (1.7%)
Hydropic abortion 1 (1.5%) 5 (0.5%)
Unknown 3 (4.6%) 17 (1.7%)
hCG pre-evacuation IU/l N = 14 N = 645
Median (range) 85 701.5 (492–1 165 760) 9654 (6–1 217 592) <0.001
hCG pre-chemotherapy IU/l N = 65 N = 330
Median (range) 14 976 (50–113 533) 11 493.5 (1–410 804) 0.169
Hysterectomy** 0 (0%) 4 (0.4%) 1.000
*Mole, not further specified.
**As primary or second-line treatment for MTX resistance; IQR, interquartile range.
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more MTX courses to achieve remission than patients
without metastases (median: nine courses in group I versus
six courses in group II). The patients with lung metastases
developed MTX resistance more frequently (60% versus
38.9%; P = 0.001), but they were also more likely to have a
higher FIGO score (Table 1; P < 0.001). Figure S1 (see
Supplementary material) shows that of the 39 patients with
lung metastases that became resistant to MTX/FA, 16
(41%) subsequently received etoposide, methotrexate, acti-
nomycin D, cyclophosphamide, vincristine (EMA/CO), and
23 (59%) received dactinomycin as second-line treatment
to induce remission. Similarly, of the 405 patients without
metastases who developed MTX resistance (n = 379) or
toxicity (n = 26), subsequent remission was induced by
EMA/CO (n = 200, 49.4%), dactinomycin (n = 200,
49.4%), carboplatin (n = 3, 0.7%) or hysterectomy (n = 2,
0.5%) (see Supplementary material, Figure S2).
Disease relapse was significantly more prevalent in
patients with lung metastases than in patients without
metastases (9.2% versus 2.7%, P = 0.012). We postulated
that the reason for the significantly increased resistance to
MTX/FA and higher recurrence rate after chemotherapy in
the lung metastases group might be a consequence of the
increased proportion of patients with a non-molar diagno-
sis such as choriocarcinoma. We therefore performed sub-
group analyses comparing patients who had post-molar
GTN with those who had choriocarcinoma or a non-molar
GTN diagnosis (Table 3). In all three subgroups, patients
with lung metastases showed a significantly increased risk
for developing resistance to MTX/FA. However, this was
most obvious in the non-molar patients. Hence, all chorio-
carcinoma patients with lung metastases and all but one
with non-molar GTN developed resistance to MTX/FA.
However, the risk of recurrence in patients with post-molar
GTN or choriocarcinoma, although higher in the lung
metastases group, was no longer significant (Table 3).
Importantly, disease-specific survival in all groups was
100%. One patient without metastases, in remission after
EMACO following MTX toxicity, died of unrelated heart
failure 8.5 years after diagnosis of GTN. Median follow-up
time of all the patients was 54 months (interquartile range
34.75–87.25 months).
Table S1 (see Supplementary material) shows the factors
affecting MTX resistance among low-risk GTN patients,
using univariate logistic regression. In the univariate analysis,
four variables were found to significantly affect MTX resis-
tance (age, interval from end of antecedent pregnancy to
treatment, pre-chemotherapy hCG values and the presence
of lung metastases). In the multivariate analysis, patients
who had a pre-chemotherapy hCG concentration of
>100 000 IU/l had a much higher risk of MTX resistance
(odds ratio [OR] 13.6, 95% CI 4.0–46.2, P < 0.001) in com-
parison with patients whose pre-chemotherapy hCG concen-
tration was <1000 IU/l. In addition, patients with lung
metastases had a three-fold excess risk of MTX resistance
compared with patients without metastases (OR 3.1, 95% CI
1.7–5.7, P < 0.001). Moreover, lung metastases were signifi-
cantly associated with recurrence of disease in univariable


















9 (7–10.25) 6 (4–7) <0.001
MTX resistance 39/65 (60%) 379/975 (38.9%) 0.001
Recurrence 6 (9.2%) 26 (2.7%) 0.012
Death of disease 0 (0%) 0 (0%) –
IQR, interquartile range.





































32/57 (56.1%) 370/936 (39.5%) 0.018 4/4 (100%) 4/17 (23.5%) 0.012 3/4 (75%) 5/22 (22.7%) 0.072
Recurrence 4/57 (6.7%) 23/936 (2.5%) 0.064 2/4 (50%) 3/17 (17.6%) 0.228 0/4 (0%) 0/22 (0%) N/A
CC, choriocarcinoma; IQR, inter quartile range.
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(OR 3.1, 95% CI 1.2–8.5, P = 0.02) and multivariable (OR
3.2, 95% CI 1.1–9.4, P = 0.04) logistic regression analyses,
adjusted for antecedent pregnancy, histopathological diagno-
sis and interval from evacuation until treatment. In addition,
we performed a weighted logistic regression analysis that also
demonstrated the presence of lung metastases as a significant
adverse factor (OR 3.2, 95% CI 1.6–6.4, P = 0.001) for
recurrence of low-risk disease.
Discussion
Main findings
This study demonstrates that the presence of lung metas-
tases upon first GTN staging is a risk factor for MTX resis-
tance and recurrence in low-risk GTN. Furthermore, a
greater number of MTX courses were needed in patients
with lung metastases to achieve remission compared with
patients without metastases.
Strengths and limitations
The influence of lung metastases has been recently investi-
gated by Vree et al.9 In this study, GTN patients (including
high-risk patients) with lung metastases showed a higher
recurrence rate (16.7% versus 2.2%, P < 0.0001) and more
disease-specific deaths (8.3% versus 0%, P < 0.0001) com-
pared with patients without metastases. The present study
confirms that low-risk patients treated with MTX have
higher recurrence rates if they have lung metastases present
(9.2% versus 2.7%, P = 0.012). However, in contrast to the
previous work, we did not validate an adverse outcome on
survival in the presence of lung metastases as disease-speci-
fic survival was 100% for all low-risk patients. Our study is
limited by the fact that it was a retrospective rather than a
prospective analysis. Furthermore, although our study has
addressed the importance of lung metastases at presenta-
tion as a potential predictor of increased risk of recurrence,
we did not look at the importance of residual lung lesions
following completion of chemotherapy. Such residual
lesions might be expected to also increase the risk of recur-
rence. However, a previous study by Powles et al. failed to
show any significant adverse effect on recurrence rate in
low-risk GTN patients with or without residual radiological
chest abnormalities following chemotherapy.16 This study
was small, with 76 patients in total of whom only 23 had
residual lung lesions visible on CXR and/or CT. Given the
present findings, it seems sensible to perform larger studies
looking at the effect of lung lesions at presentation and on
completion of therapy for their effect on recurrence rates
for GTN. Finally, a time-to-event analysis was not used but
data were analysed as a binary (yes/no) outcome instead.
The results from this method are valid under the assump-
tion that all patients have been followed for the complete
course of the disease.
Despite these limitations, we included a large homoge-
neous group of patients that were treated in a specialised
centre with long-term follow up. In addition, all patients
underwent centralised pathological review and imaging. As
all GTN cases are centrally registered in the UK, the possi-
bility of case ascertainment bias is exceptionally small.
Interpretation
Patients with choriocarcinoma had a higher risk of recur-
rence compared with patients with post-molar GTN
(Table 3). This raises the question as to whether it is safe
to consider choriocarcinoma with lung metastases as low-
risk disease even if that is the FIGO score result. Indeed, all
four choriocarcinoma patients with lung metastases devel-
oped MTX resistance. Primary multi-agent chemotherapy
such as EMA/CO would have been more appropriate for
these women. Similarly, most non-molar GTN patients
with lung metastases ended up requiring EMA/CO therapy.
In contrast, choriocarcinoma patients without metastases in
the lung or at other metastatic sites were often cured
(76.5%) with MTX/FA (Table 3) as were the post-molar
cases without lung metastases. Consequently, patients with
choriocarcinoma or non-molar GTN without lung metas-
tases can reasonably start MTX/FA but those with lung
metastases are best given multi-agent chemotherapy from
the outset. However, further research is needed to confirm
our findings in larger patient cohorts.
Higher pre-treatment hCG levels have been associated
with an increased risk of initial chemotherapy resistance
in low-risk GTN.17–19 This is in accordance with our find-
ings that patients with lung metastases and higher hCG
levels showed more MTX resistance (60% versus 38.9%;
P = 0.001). Moreover, multivariate regression analysis
demonstrated high pre-treatment hCG levels and the pres-
ence of lung metastases as significant adverse factors
affecting MTX resistance (see Supplementary material,
Table S1). The high hCG level reflects higher tumour bur-
den. It is therefore not surprising that more courses of
chemotherapy were needed to achieve complete remission
in this group.
Previous studies have reported the effect of metastatic
disease on response to single-agent chemotherapy in low-
risk disease.17,20–23 Chapman-Davis et al. found an
increased rate of resistance to initial chemotherapy in low-
risk GTN patients with metastases (53 lung, 5 vagina and 1
pelvis) compared with the group without metastases (31%
versus 17%; P = 0.018).17 Mousavi et al. did not further
specify metastatic disease, but higher risk of resistance was
found among low-risk GTN patients with metastases
(OR = 8.42, P = 0.001) compared with patients without
metastases.21 Furthermore, Darby et al. found that low-risk
GTN patients with lung metastases were more likely to
need the switch to second-line chemotherapy than patients
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with non-metastatic GTN (OR = 2.25, P = 0.016).20 Addi-
tionally, the presence of lung metastases was an indepen-
dent predictor of requiring additional MTX courses and
alternative chemotherapy for women with low-risk GTN in
the study of Growdon et al.23 The mechanisms of
chemotherapeutic resistance in GTN are still unclear. In
acquired drug resistance, tumours are initially responsive,
but become resistant with continued treatment. Hence
smaller tumours without metastatic disease are more likely
to be cured before multiple resistant cells have evolved.
Lung metastases can be detected on CXR or CT scan the
latter being able to detect much smaller lesions of question-
able significance. Indeed, the significance of metastases that
are undetected by CXR but present on chest CT has been
examined in multiple previous GTN studies with conflict-
ing results. Some studies identified the presence of metas-
tases seen on chest CT but not CXR as a significant
prognostic factor for the development of resistance to sin-
gle-agent chemotherapy24 or a need to change from first-
line therapy.22,25 In contrast, other studies concluded that
metastases detected by chest CT alone did not affect the
clinical outcome of patients.20,26,27 For this reason, chest
CT is not routinely undertaken in patients developing GTN
following a molar pregnancy. In the present study, we can-
not exclude that some patients included in the non-meta-
static group have small lung metastases as chest CT scans
are not standard procedure. Therefore, we cannot properly
determine the importance of the <1 cm CT lesions not
seen on CXR.
It is still a matter of debate whether two or three consol-
idation courses have to be administered after normalisation
of hCG. In the only study comparing two and three
courses,28 the recurrence rate was significantly lower after
three courses of single-agent chemotherapy (4.0% versus
8.3%). However, in the group with two consolidation
courses, more patients with lung metastases were present.
Indeed, in the current study, 9.2% of the patients with lung
metastases had a recurrence. Lung metastases may not
completely explain the difference in recurrence rate, but it
is tempting to speculate that this specific patient group
with lung metastases may benefit from more than two
courses of consolidation therapy.
Conclusion
In summary, the presence of lung metastases appears to
have an adverse influence on the clinical course of disease
in low-risk GTN.9 However, the prognosis of low-risk
patients treated in a specialised trophoblastic disease centre
is excellent, with a cure rate of 100%. Choriocarcinoma
patients with lung metastases are likely to become resistant
to MTX and primary multi-agent chemotherapy such as
EMA/CO should be considered. The presence of lung
metastases at presentation does increase the risk of MTX
resistance and recurrence of disease but it is not an inde-
pendent prognostic factor in the FIGO score because it is
accounted for by the number of metastases and tumour
size. Therefore an adjustment of current scoring systems to
value lung metastases differently does not yet seem justi-
fied.
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Fig S1. Remission rates after methotrexate treatment for
patients with lung metastases.
Fig S2. Remission rates after methotrexate treatment for
patients without lung metastases.
Table S1. Factors affecting methotrexate resistance
among individuals with low-risk gestational trophoblastic
neoplasia.&
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